Environmental Sciences Division, National Exposure Research Laboratory, U.S. Environmental Protection Agency, 944 East Harmon Ave, Las Vegas, NV 89119, United States.
Sci Total Environ. 2014 Sep 15;493:392-404. doi: 10.1016/j.scitotenv.2014.06.013. Epub 2014 Jun 20.
Active pharmaceutical ingredients (APIs) from the purchase and use of medications are recognized as ubiquitous contaminants of the environment. Ecological impacts can range from subtle to overt--resulting from multi-generational chronic exposure to trace levels of multiple APIs (such as in the aquatic environment) or acute exposure to higher levels (such as with wildlife ingestion of improperly discarded waste). Reducing API entry to the environment has relied solely on conventional end-of-pipe pollution control measures such as wastewater treatment and take-back collections of leftover, unwanted drugs (to prevent disposal by flushing to sewers). An exclusive focus on these conventional approaches has ignored the root sources of the problem and may have served to retard progress in minimizing the environmental footprint of the healthcare industry. Potentially more effective and less-costly upstream pollution prevention approaches have long been considered imprudent, as they usually involve the modification of long-established norms in the practice of clinical prescribing. The first pollution prevention measure to be proposed as feasible (reducing the dose or usage of certain select medications) is followed here by an examination of another possible approach--one that would rely on the excretion profiles of APIs. These two approaches combined could be termed eco-directed sustainable prescribing (EDSP) and may hold the potential for achieving the largest reductions in API entry to the environment--largely by guiding prescribers' decisions regarding drug selection. EDSP could reduce API entry to the environment by minimizing the need for disposal (as a consequence of avoiding leftover, unwanted medications) and reducing the excretion of unmetabolized APIs (by preferentially prescribing APIs that are more extensively metabolized). The potential utility of the Biopharmaceutics Drug Disposition Classification System (BDDCS) is examined for the first time as a guide for API prescribing decisions by revealing relative API quantities entering sewage via excretion.
活性药物成分 (API) 来自药物的购买和使用,被认为是环境中无处不在的污染物。生态影响范围从微妙到明显——由于多代慢性暴露于痕量的多种 API(如在水生环境中)或急性暴露于更高水平(如野生动物摄入不当丢弃的废物)而导致。减少 API 进入环境的方法仅依赖于传统的末端治理污染控制措施,例如废水处理和回收剩余的、不需要的药物(以防止通过冲洗下水道而丢弃)。这种单纯关注传统方法的做法忽视了问题的根源,可能阻碍了减少医疗保健行业环境足迹的进展。长期以来,人们一直认为更有效的、成本更低的上游污染预防方法是不明智的,因为它们通常涉及到临床处方实践中长期确立的规范的修改。本文首先提出了一种可行的污染预防措施(减少某些特定药物的剂量或使用量),然后考察了另一种可能的方法——一种依赖于 API 排泄特征的方法。这两种方法结合起来可以称为生态导向可持续处方 (EDSP),并有可能实现对 API 进入环境的最大减少——主要是通过指导医生在药物选择方面的决策。EDSP 可以通过最小化处置的需求(避免剩余的、不需要的药物)和减少未代谢的 API 的排泄(优先开代谢更广泛的 API)来减少 API 进入环境。本文首次考察了生物药剂学药物处置分类系统 (BDDCS) 的潜在效用,作为通过排泄进入污水的相对 API 量来指导 API 处方决策的指南。